Navigation Links
Arpida Reports Interim Results for Six Months to 30 June 2008
Date:8/20/2008

James Bruno to Lead Arpida's North-American Commercial Operations

REINACH, Switzerland, August 20 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the six months ending 30 June 2008.
Highlights 2008 to date

Major pipeline progress:

- Regulatory filings for intravenous iclaprim in cSSSI submitted in

U.S.A. and Europe

- Enrolment in Phase II "intravenous-to-oral" switch trial with oral

iclaprim progresses well

- Enrolment in Phase II HAP/VAP/HCAP trial challenging

- Enrolment in Phase III trial with TLT approaches 50%

- Leadership change to enable Arpida to become a fully integrated

pharmaceutical company

- Raised CHF 19.6 million in a secondary offering in April 2008

- Cash and financial investments of CHF 67.9 million at 30 June 2008

CFO Harry Welten, MBA, commented: "Thanks to continued focus we have managed to keep spending in the first half of 2008 within the guidance given in March this year. Due to the build-up of commercial capabilities, we expect cash spending on operating activities in the second half of 2008 to be around CHF 4.5 million on average per month. Based on our financial position and iclaprim's advanced development status, we feel we are well-placed as we approach 2009, which we expect to be a launch year."

Dr J├╝rgen Raths, President and CEO, commented: "I am very pleased with the achievements in the year to date, not only in financial terms, but also in terms of development and regulatory progress. Our lead product candidate iclaprim is now under review at the major regulatory authorities on both sides of the Atlantic. We are very much looking forward to hearing from the U.S. authorities in January 2009. After more than 10 years of hard work, Arpida is getting very close to turning what used to be a promising compound into a promising drug, providing physicians with a potent new therapy in the
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... -- Wockhardt Limited today announces a major boost to ... two of its drugs, WCK 771 and WCK 2349, ... from U.S. Food & Drug Administration (FDA).  QIDP status ... have a high degree of unmet need in their ... (a top U.S. government health and safety body).  QIDP ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... CARLSBAD, Calif., Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ... of,Directors has promoted B. Lynne Parshall, J.D. to ... position as Chief Financial,Officer, and is a Director ... and appropriately reflects the scope,of Lynne,s responsibilities at ...
... /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today announced ... its asthma diagnostic tool, Aridol in Portugal., ... included in the,successful mutual recognition procedure earlier this ... "Bronchial challenge testing is a common procedure ...
... Corporation (NYSE:,FMC) and Pronova BioPharma ASA (OSE: ... a worldwide license and development agreement to ... by FMC. The,alginate-based capsule technology is expected ... Pronova BioPharma,s products and has,the potential for ...
Cached Biology Technology:Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3Pharmaxis Appoints Portuguese Distributor for Aridol 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... a history of scientific research on mountain ecosystems, ... systems, and sets an agenda for biodiversity conservation ... "Mountain gloom and mountain glory revisited: A survey ... regions," appears online in the Journal of ... of Tufts University, Jodi A. Hilty of the ...
(Date:9/2/2014)... JUPITER, FL, September 2, 2014 In a new ... scientists from the Florida campus of The Scripps Research ... diseased cells into unique manufacturing sites for molecules that ... using a cell as a reaction vessel and a ... in a diseased cell," said TSRI Professor Matthew Disney.,"Because ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Scripps Florida scientists make diseased cells synthesize their own drug 2
... turtles are too optimistic, according to Loren McClenachan ... McClenachan, Jeremy Jackson and Marah Newman agree ... helped increase green and hawksbill turtle populations that ... that dwindling turtle populations on many historically important ...
... population in New Hampshire's Great Bay estuary has plummeted by ... disease MSX. The previous century saw a slower but equally ... local extinction on some reefs," says Ray Grizzle, research associate ... , Now Grizzle is working to bring oysters back ...
... a surprisingly high percentage of people with type 1 ... years or longer (The Joslin Medalists) may still have ... The findings will be presented June 12 at the ... Washington, D.C. , "It is surprising that some ...
Cached Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3